Fractyl Health, Inc. Common Stock (GUTS) 10-Year Financial Performance & Capital Metrics

GUTS • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.Show more

Revenue $93K -22.5%
EBITDA -$93M -83.7%
Net Income -$69M +10.9%
EPS (Diluted) -1.62 +18.2%
Gross Margin 46.24% +29.0%
EBITDA Margin -99843.01% -137.0%
Operating Margin -100570.97% -137.4%
Net Margin -73864.52% -15.0%
ROE -241.68%
ROIC -363.51% +3.0%
Debt/Equity 2.20
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 91 (top 9%)
✓Share count reduced 8.5% through buybacks

✗Weaknesses

✗High debt to equity ratio of 2.2x
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-96.91%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-94.26%

EPS CAGR

10Y-

5Y-

3Y-

TTM-68.89%

ROCE

10Y Avg-182.11%

5Y Avg-110.27%

3Y Avg-94.07%

Latest-122%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.73B	5.64	58.02	43.5%	9.32%		1.89%
CORTCorcept Therapeutics Incorporated	3.82B	36.35	29.55	39.94%	14.19%	16.65%	5.12%	0.01
GUTSFractyl Health, Inc. Common Stock	308.28M	2.01	-1.24	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	436.08M	1.20	-1.90	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	229.96M	2.48	-2.53			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	164.38M	1.93	-2.88	-100%		-282.97%		4.17
ALTAltimmune, Inc.	418.41M	4.01	-2.99	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	741.84M	20.69	-3.12		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	120K	93K
Revenue Growth %	-	-	-	-	-	-0.23%
Cost of Goods Sold+	893K	770K	0	452K	77K	50K
COGS % of Revenue	-	-	-	-	0.64%	0.54%
Gross Profit+	-893K	-770K	0	-452K	43K	43K
Gross Margin %	-	-	-	-	0.36%	0.46%
Gross Profit Growth %	-	0.14%	1%	-	1.1%	0%
Operating Expenses+	29.03M	28.19M	36.93M	48.93M	50.88M	93.57M
OpEx % of Revenue	-	-	-	-	423.99%	1006.17%
Selling, General & Admin	8.14M	5.76M	10.49M	14.58M	0	0
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	20.89M	22.43M	26.43M	34.35M	38.04M	70.47M
R&D % of Revenue	-	-	-	-	316.98%	757.75%
Other Operating Expenses	0	0	0	0	12.84M	23.1M
Operating Income+	-29.92M	-28.96M	-36.93M	-49.38M	-50.84M	-93.53M
Operating Margin %	-	-	-	-	-423.63%	-1005.71%
Operating Income Growth %	-	0.03%	-0.28%	-0.34%	-0.03%	-0.84%
EBITDA+	-29.03M	-28.19M	-36.25M	-48.93M	-50.55M	-92.85M
EBITDA Margin %	-	-	-	-	-421.25%	-998.43%
EBITDA Growth %	-	0.03%	-0.29%	-0.35%	-0.03%	-0.84%
D&A (Non-Cash Add-back)	893K	770K	676K	452K	286K	677K
EBIT	-29.92M	-28.96M	-36.93M	-49.38M	-50.84M	-93.53M
Net Interest Income+	-635K	-1.5M	-1.44M	797K	1.26M	4.15M
Interest Income	0	0	0	797K	1.26M	4.15M
Interest Expense	635K	1.5M	1.44M	0	0	0
Other Income/Expense	-673K	-1.52M	-1.81M	2.93M	-26.25M	24.84M
Pretax Income+	-30.59M	-30.48M	-38.73M	-46.45M	-77.09M	-68.69M
Pretax Margin %	-	-	-	-	-642.42%	-738.65%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-30.59M	-30.48M	-38.73M	-46.45M	-77.09M	-68.69M
Net Margin %	-	-	-	-	-642.42%	-738.65%
Net Income Growth %	-	0%	-0.27%	-0.2%	-0.66%	0.11%
Net Income (Continuing)	-30.59M	-30.48M	-38.73M	-46.45M	-77.09M	-68.69M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.64	-0.86	-1.12	-1.34	-1.98	-1.62
EPS Growth %	-	-0.34%	-0.3%	-0.2%	-0.48%	0.18%
EPS (Basic)	-0.64	-0.86	-1.12	-1.34	-1.98	-1.62
Diluted Shares Outstanding	47.61M	47.61M	47.61M	47.61M	47.61M	43.54M
Basic Shares Outstanding	47.61M	47.61M	47.61M	47.61M	47.61M	43.54M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.78M	30.88M	96.39M	51.63M	35.65M	71.76M
Cash & Short-Term Investments	5.79M	29.11M	95.47M	49.27M	33.52M	67.46M
Cash Only	5.79M	29.11M	95.47M	49.27M	33.52M	67.46M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	22K	0
Days Sales Outstanding	-	-	-	-	66.92	-
Inventory	0	0	0	0	73K	73K
Days Inventory Outstanding	-	-	-	-	346.04	532.9
Other Current Assets	0	0	915K	2.36M	2.03M	4.23M
Total Non-Current Assets+	2.16M	3.88M	6.16M	9.33M	40.56M	36.31M
Property, Plant & Equipment	2.12M	1.36M	1.34M	1.65M	30.77M	31.39M
Fixed Asset Turnover	-	-	-	-	0.00x	0.00x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	863K	835K	0
Long-Term Investments	0	0	0	4.25M	4.25M	4.25M
Other Non-Current Assets	32K	2.52M	4.82M	2.56M	4.7M	666K
Total Assets+	8.93M	34.76M	102.55M	60.96M	76.21M	108.08M
Asset Turnover	-	-	-	-	0.00x	0.00x
Asset Growth %	-	2.89%	1.95%	-0.41%	0.25%	0.42%
Total Current Liabilities+	3.41M	10.92M	23.65M	7.31M	11.19M	19.77M
Accounts Payable	608K	304K	970K	980K	553K	3.24M
Days Payables Outstanding	248.51	144.1	-	791.37	2.62K	23.65K
Short-Term Debt	0	7.17M	15.72M	0	2.73M	0
Deferred Revenue (Current)	0	0	-970K	-980K	0	0
Other Current Liabilities	1.94M	672K	5.13M	3.3M	4.4M	7.39M
Current Ratio	1.99x	2.83x	4.07x	7.06x	3.19x	3.63x
Quick Ratio	1.99x	2.83x	4.07x	7.06x	3.18x	3.63x
Cash Conversion Cycle	-	-	-	-	-2.21K	-
Total Non-Current Liabilities+	149.52M	8.89M	288.22M	305.96M	390.09M	59.88M
Long-Term Debt	14.9M	8.12M	287.33M	305.09M	342.48M	30.16M
Capital Lease Obligations	0	0	334K	465K	28.51M	27.38M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	134.62M	769K	555K	409K	19.1M	2.33M
Total Liabilities	152.93M	19.81M	311.87M	313.27M	401.27M	79.65M
Total Debt+	148.01M	15.29M	304.34M	306.81M	373.72M	62.5M
Net Debt	142.22M	-13.81M	208.87M	257.54M	340.2M	-4.96M
Debt / Equity	-	1.02x	-	-	-	2.20x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-47.12x	-19.27x	-25.61x	-	-	-
Total Equity+	-144M	14.95M	-209.32M	-252.32M	-325.06M	28.42M
Equity Growth %	-	1.1%	-15%	-0.21%	-0.29%	1.09%
Book Value per Share	-3.02	0.31	-4.40	-5.30	-6.83	0.65
Total Shareholders' Equity	-144M	14.95M	-209.32M	-252.32M	-325.06M	28.42M
Common Stock	20.75M	0	0	0	0	0
Retained Earnings	-153.86M	-184.34M	-223.07M	-269.52M	-346.62M	-415.31M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-153.86M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-27.73M	-31.07M	-33.46M	-46.24M	-42.82M	-65.52M
Operating CF Margin %	-	-	-	-	-356.86%	-704.53%
Operating CF Growth %	-	-0.12%	-0.08%	-0.38%	0.07%	-0.53%
Net Income	-30.59M	-30.48M	-38.73M	-46.45M	-77.09M	-68.69M
Depreciation & Amortization	893K	770K	676K	452K	286K	677K
Stock-Based Compensation	2.52M	1.63M	2.09M	3.14M	4.3M	14.43M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	274K	517K	795K	-2.14M	28.7M	-21.52M
Working Capital Changes	-824K	-3.51M	1.71M	-1.24M	989K	9.59M
Change in Receivables	0	0	0	0	-22K	22K
Change in Inventory	0	0	0	0	-73K	0
Change in Payables	0	-304K	666K	0	-427K	2.69M
Cash from Investing+	-97K	-2K	-51K	-56K	-359K	-1.76M
Capital Expenditures	-97K	-2K	-51K	-56K	-359K	-1.76M
CapEx % of Revenue	-	-	-	-	2.99%	18.98%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	15.16M	54.39M	99.88M	4.35M	27.44M	101.23M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	217K	24K	40K	0	-911K	-2.28M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-27.83M	-31.07M	-33.51M	-46.3M	-43.18M	-67.29M
FCF Margin %	-	-	-	-	-359.85%	-723.51%
FCF Growth %	-	-0.12%	-0.08%	-0.38%	0.07%	-0.56%
FCF per Share	-0.58	-0.65	-0.70	-0.97	-0.91	-1.55
FCF Conversion (FCF/Net Income)	0.91x	1.02x	0.86x	1.00x	0.56x	0.95x
Interest Paid	0	1.04M	1.03M	0	762K	3.13M
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-203.87%	-	-	-	-241.68%
Return on Invested Capital (ROIC)	-	-	-8181.98%	-1557.23%	-374.68%	-363.51%
Gross Margin	-	-	-	-	35.83%	46.24%
Net Margin	-	-	-	-	-64242.5%	-73864.52%
Debt / Equity	-	1.02x	-	-	-	2.20x
Interest Coverage	-47.12x	-19.27x	-25.61x	-	-	-
FCF Conversion	0.91x	1.02x	0.86x	1.00x	0.56x	0.95x
Revenue Growth	-	-	-	-	-	-22.5%

Frequently Asked Questions

Growth & Financials

Fractyl Health, Inc. Common Stock (GUTS) reported $0.0M in revenue for fiscal year 2024.

Fractyl Health, Inc. Common Stock (GUTS) saw revenue decline by 22.5% over the past year.

Fractyl Health, Inc. Common Stock (GUTS) reported a net loss of $122.2M for fiscal year 2024.

Dividend & Returns

Fractyl Health, Inc. Common Stock (GUTS) has a return on equity (ROE) of -241.7%. Negative ROE indicates the company is unprofitable.

Fractyl Health, Inc. Common Stock (GUTS) had negative free cash flow of $86.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener